TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22545928

Group type: EXPERIMENTAL
Intervention: Cognitive-based test of deception measuring ocular-motor responses (pupil responses and reading behaviors) during a computerized questionnaire.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-based test of deception with increased incentives to pass the test and simple syntax statements.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ocular-motor measures used in a discrimination function.
Number of subjects: 0
Study: 18547784

Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 119
Study: 17804680

Group type: EXPERIMENTAL
Intervention: Meals rich in oleic acid
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Meals rich in EPA and DHA
Number of subjects: 11

Group type: COMPARATOR
Intervention: Meals rich in palmitic acid
Number of subjects: 11

Group type: COMPARATOR
Intervention: Meals rich in linoleic acid
Number of subjects: 11
Study: 15459584

Group type: EXPERIMENTAL
Intervention: Fibrinolytic agents (ASSENT-2 trial participants)
Number of subjects: 3741

Group type: COMPARATOR
Intervention: Fibrinolytic agents (non-A2 patients at trial hospitals)
Number of subjects: 3741

Group type: COMPARATOR
Intervention: Fibrinolytic agents (non-A2-Hosp patients)
Number of subjects: 3741
Study: 12492612

Group type: EXPERIMENTAL
Intervention: Chloramphenicol (25 mg kg‐1 6 hourly for 72 h) + Fosphenytoin (18 mg kg‐1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fosphenytoin (18 mg kg‐1) + Cefotaxime (25 mg kg‐1 8 hourly for 72 h)
Number of subjects: 28
Study: 9828778

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.2%
Number of subjects: 71

Group type: COMPARATOR
Intervention: Natamycin 2.5%
Number of subjects: 71
Study: 7926381

Group type: EXPERIMENTAL
Intervention: IDDM with microangiopathy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IDDM without microangiopathy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 55
Study: 2790218

Group type: EXPERIMENTAL
Intervention: Total abstinence from alcohol without disulfiram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detoxification while taking disulfiram
Number of subjects: 0
Study: 776348

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (Prothromplex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous vitamin K1 (2-5 mg)
Number of subjects: 0
Study: 31074236

Group type: COMPARATOR
Intervention: CCRT with weekly cisplatin followed by observation (arm A)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: ACT with paclitaxel plus carboplatin every 4 weeks for 3 cycles (arm B)
Number of subjects: 259
Study: 28221668

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) - moderate PA including walking, resistance and balance training
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health Education (HE) - consisting of topics relevant to older adults
Number of subjects: 1635
Study: 25846209

Group type: EXPERIMENTAL
Intervention: rBet v 1 tablets (12.5-50 μg) administered once daily for 5 months
Number of subjects: 483
Study: 23780805

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 26
Study: 21827215

Group type: EXPERIMENTAL
Intervention: St John's Wort (SJW) 325 mg three times daily for 14 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: St John's Wort (SJW)
Number of subjects: 15
Study: 19019686

Group type: EXPERIMENTAL
Intervention: FTa angle assessment
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: FTb angle measurement
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Short knee images
Number of subjects: 68
Study: 17289297

Group type: EXPERIMENTAL
Intervention: Behavioral economic measure of alcohol demand (demand curves)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: O(max) (maximum alcohol expenditure)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Breakpoint (sensitivity of consumption to increasing price)
Number of subjects: 51
Study: 14736787

Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11776596

Group type: EXPERIMENTAL
Intervention: RT‐PCR for CEA mRNA detection
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: RIA for CEA protein detection
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cytologic examination of peritoneal washings
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CEA mRNA expression
Number of subjects: 53
Study: 15251534

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose pure follicle-stimulating hormone (FSH)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Human menopausal gonadotropins (hMG)
Number of subjects: 32
Study: 1622160

Group type: EXPERIMENTAL
Intervention: 400 mg loracarbef
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 200 mg loracarbef
Number of subjects: 6

Group type: COMPARATOR
Intervention: Killing curves against 12 strains of bacteria
Number of subjects: 6
Study: 6151506

Group type: EXPERIMENTAL
Intervention: bopindolol
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 369
Study: 30690509

Group type: EXPERIMENTAL
Intervention: Anti-gp41 antibody levels
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Duration of viral suppression
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: HIV-1 DNA levels
Number of subjects: 683
Study: 29601897

Group type: EXPERIMENTAL
Intervention: Topical capsaicin and warmth
Number of subjects: 85

Group type: COMPARATOR
Intervention: Active control (warmth)
Number of subjects: 85
Study: 27548448

Group type: EXPERIMENTAL
Intervention: Intravitreal ocriplasmin 125 µg injection
Number of subjects: 0
Study: 26510099

Group type: EXPERIMENTAL
Intervention: Integrated literacy- and math-focused preschool curriculum with explicit socioemotional lesson component
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Integrated literacy- and math-focused preschool curriculum without explicit socioemotional lesson component
Number of subjects: 760

Group type: COMPARATOR
Intervention: Business-as-usual condition
Number of subjects: 760
Study: 23535809

Group type: EXPERIMENTAL
Intervention: Ice slushy ingestion (ICE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Thermoneutral liquid (CON)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thermoneutral liquid consumption with expectorated ice slushy mouthwash (WASH)
Number of subjects: 10
Study: 21157047

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.06%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.02%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no chlorhexidine)
Number of subjects: 40
Study: 18849193

Group type: EXPERIMENTAL
Intervention: Prednisolone (60 mg per day for 5 days, then reduced by 10 mg per day for a total of 10 days)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Valaciclovir (1000 mg three times per day for 7 days)
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Prednisolone plus valaciclovir
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 829
Study: 15914049

Group type: EXPERIMENTAL
Intervention: Durogesic fentanyl transdermal reservoir (TDF)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Oral sustained-release morphine (SRM)
Number of subjects: 680
Study: 12806323

Group type: EXPERIMENTAL
Intervention: Conservative endodontic access
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Removal of all cusps
Number of subjects: 90

Group type: COMPARATOR
Intervention: Other groups (7 groups with varying degrees of tooth loss)
Number of subjects: 90
Study: 11106307

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg i.v.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8657447

Group type: EXPERIMENTAL
Intervention: Zantac (histamine H2-receptor antagonist)
Number of subjects: 64
Study: 1310921

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 10 micrograms min‐1 kg‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 2 and 5 micrograms min‐1 kg‐1
Number of subjects: 8
Study: 6432353

Group type: EXPERIMENTAL
Intervention: ACF (adriamycin, cyclophosphamide, ftorafur)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ACFM (adriamycin, cyclophosphamide, ftorafur, methotrexate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ACF
Number of subjects: 60

Group type: COMPARATOR
Intervention: ACFM
Number of subjects: 60
Study: 30627737

Group type: EXPERIMENTAL
Intervention: midazolam 50 µg/ml plus lidocaine 2% and hyaluronidase 15 IU/ml (Group M1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: midazolam 100 µg/ml plus lidocaine 2% and hyaluronidase 15 IU/ml (Group M2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: lidocaine 2% and hyaluronidase 15 IU/ml (Group C)
Number of subjects: 90
Study: 29469951

Group type: EXPERIMENTAL
Intervention: Lorazepam as an adjuvant to haloperidol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo as an adjuvant to haloperidol
Number of subjects: 90
Study: 27655031

Group type: EXPERIMENTAL
Intervention: High-fiber meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-fiber meal
Number of subjects: 20
Study: 24519039

Group type: EXPERIMENTAL
Intervention: peginterferon‐α2a and 800 mg daily dose of ribavirin
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: ITPA gene variants predicting reduced ITPase activity
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Homozygous for both major alleles (normal ITPase activity)
Number of subjects: 354
Study: 23023457

Group type: EXPERIMENTAL
Intervention: Dog bite prevention report (PAR‐DB)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Other safety behaviors report (PAR‐S)
Number of subjects: 901
Study: 20202351

Group type: EXPERIMENTAL
Intervention: Point-of-care testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pathology laboratory testing
Number of subjects: 0
Study: 17541262

Group type: EXPERIMENTAL
Intervention: Respironics REMstar Auto (RR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ResMed Spirit (RS)
Number of subjects: 50
Study: 15673895

Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: bupivacaine (7.5 mg)
Number of subjects: 0
Study: 12559222

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 203

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 203
Study: 10577621

Group type: EXPERIMENTAL
Intervention: Loop diathermy
Number of subjects: 222

Group type: COMPARATOR
Intervention: Laser conization
Number of subjects: 222
Study: 8314652

Group type: EXPERIMENTAL
Intervention: Single oral doses of E2020 (0.3 mg, 1 mg, 2 mg, 5 mg, 8 mg, 10 mg) in fasting condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single oral dose of E2020 (2 mg) after a meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated oral doses of E2020 (2 mg once daily for 21 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single oral dose of E2020 (10 mg)
Number of subjects: 0
Study: 3034017

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg once daily
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg once daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 29800767

Group type: EXPERIMENTAL
Intervention: Shame induction
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Guilt induction
Number of subjects: 141

Group type: COMPARATOR
Intervention: Neutral induction
Number of subjects: 141
Study: 27665708

Group type: EXPERIMENTAL
Intervention: Standing for 1 minute after seated SBP measurements
Number of subjects: 8662

Group type: EXPERIMENTAL
Intervention: Factors associated with changes in BP upon standing
Number of subjects: 8662
Study: 25959271

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg daily for six weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 23848435

Group type: EXPERIMENTAL
Intervention: Definite acute exacerbation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Suspected acute exacerbation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Other
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Definite and suspected acute exacerbations
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Respiratory serious adverse events
Number of subjects: 35
Study: 20850327

Group type: EXPERIMENTAL
Intervention: Hamstring (HT) autografts
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB) autografts
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Four-strand HT combined with modern endobutton HT graft-fixation technique
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Both HT and BPTB autografts
Number of subjects: 1643
Study: 19567528

Group type: EXPERIMENTAL
Intervention: Testosterone low dose (T-LD) 0.75 mg/12 h iv
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Testosterone high dose (T-HD) 2.5 mg/12 h iv
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (baseline)
Number of subjects: 14
Study: 16919138

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 16279280

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 11775648

Group type: EXPERIMENTAL
Intervention: Essaven gel (EG) applied locally for 2 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 35
Study: 9534493

Group type: EXPERIMENTAL
Intervention: Standardized protocol for measurement of shoulder movements using the Plurimeter-V inclinometer
Number of subjects: 6
Study: 7746029

Group type: EXPERIMENTAL
Intervention: Bretazenil 0.25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bretazenil 0.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2728956

Group type: EXPERIMENTAL
Intervention: Videotaped training program on resisting pressures to smoke
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study: 30084098

Group type: EXPERIMENTAL
Intervention: Topical application of honey on oral mucosa
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine practice of analgesic and antiseptic gel application (Control)
Number of subjects: 100
Study: 28615010

Group type: EXPERIMENTAL
Intervention: Internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 26147236

Group type: EXPERIMENTAL
Intervention: Cognitive Symptom Management and Rehabilitation Therapy (CogSMART), a 12‐session, manualized compensatory cognitive training intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Supported employment combined with compensatory cognitive training (CogSMART)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Supported employment only
Number of subjects: 50
Study: 24592578

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 34
Study: 21664068

Group type: EXPERIMENTAL
Intervention: Naftopidil
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 212
Study: 18622361

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17069545

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12688593

Group type: COMPARATOR
Intervention: Embryo transfer on day 1
Number of subjects: 329

Group type: COMPARATOR
Intervention: Embryo transfer on days 2 and 3
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Embryo transfer on days 4 and 5
Number of subjects: 329
Study: 10737166

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low-flux haemodialysis (HD)
Number of subjects: 44
Study: 9186317

Group type: EXPERIMENTAL
Intervention: 100 mg/kg OTZ
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 70 mg/kg OTZ
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8383319

Group type: EXPERIMENTAL
Intervention: Glyceryltrinitrate (GTN) ointment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heparinoid ointment (Control)
Number of subjects: 40
Study: 3022628

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB) 1.5 mg/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB) and Placebo
Number of subjects: 18
Study: 30374129

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza virus
Number of subjects: 0
Study: 27171324

Group type: EXPERIMENTAL
Intervention: Albuterol (9 puffs for up to 15 kg, 12 puffs for >15-20 kg, 15 puffs for >20-25 kg, 18 puffs for >25 kg)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (6 puffs for up to 25 kg, 12 puffs for >25 kg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Albuterol (various dosages as per weight)
Number of subjects: 119
Study: 23328180

Group type: EXPERIMENTAL
Intervention: Topical application of mitomycin-C (0.4 mg/ml) adjuncted with interventional bronchoscopy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Interventional bronchoscopy only (control group)
Number of subjects: 20
Study: 20191257

Group type: EXPERIMENTAL
Intervention: Fiber group (oat-bran 5.2g/d for 84 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (ward's habitual diet)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fiber group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 18360047

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-ARB treatment
Number of subjects: 100
Study: 15951472

Group type: EXPERIMENTAL
Intervention: Simulated microgravity (smuG)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal gravity (1G)
Number of subjects: 6
Study: 12638278

Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Number of subjects: 16
Study: 11563410

Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg administered 10 minutes before a high-fat breakfast meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg administered immediately after a high-fat breakfast meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nateglinide 30 mg and 60 mg under fasting conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nateglinide taken prior to the meal
Number of subjects: 12
Study: 8955514

Group type: EXPERIMENTAL
Intervention: Middle-aged men
Number of subjects: 2

Group type: COMPARATOR
Intervention: Young men
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 2
Study: 1819709

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2.16 g per day for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Olive oil 12 g per day for 4 weeks
Number of subjects: 12
Study: 7288877

Group type: EXPERIMENTAL
Intervention: Behavioral contracting (with or without family involvement) and weekly telephone contacts
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study: 30160369

Group type: EXPERIMENTAL
Intervention: Standard postoperative G‐tube care
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Standard hydrocolloid G‐tube dressing
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Silver‐impregnated hydrocolloid G‐tube dressing
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Patients who developed hypergranulation tissue
Number of subjects: 171

Group type: COMPARATOR
Intervention: Patients who did not develop hypergranulation tissue
Number of subjects: 171
Study: 27756804

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) and adjunctive intra-arterial mechanical thrombectomy (MT)
Number of subjects: 65
Study: 26542104

Group type: EXPERIMENTAL
Intervention: Combined functional rehabilitation program (8 weeks, 3 days per week, 30-min sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional health education program (once a month over 8 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined functional rehabilitation program
Number of subjects: 40
Study: 23535007

Group type: EXPERIMENTAL
Intervention: Preoperative ibuprofen continued for a week
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intraoperative dexamethasone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Preoperative ibuprofen continued for a week + Intraoperative dexamethasone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 21112746

Group type: EXPERIMENTAL
Intervention: Amisulpride 25mg bid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoxetine 20mg uid
Number of subjects: 40
Study: 19734682

Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus gasseri OLL2809 (100 mg per day for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16770979

Group type: EXPERIMENTAL
Intervention: Educational intervention group
Number of subjects: 1446

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1446
Study: 15867741

Group type: EXPERIMENTAL
Intervention: Glycerin suppository
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual ostomy emptying practice
Number of subjects: 0
Study: 11275800

Group type: EXPERIMENTAL
Intervention: EMLA cream applied to the ulcer for 30-45 minutes under occlusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 0
Study: 9428981

Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) 0.1 mg/kg x d
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) 0.05 mg/kg x d
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128